Why did the FDA decline Moderna's flu shot?
Regulators, scientists and industry react
U.S. regulators notified Moderna that they will not accept the company’s application to license an mRNA-based influenza vaccine for formal review. The agency said the company’s pivotal trial did not meet the standard of an "adequate and well‑controlled" comparison, citing the choice of comparator and study design. Agency reviewers and outside experts have flagged those problems as the core reason the application was declined.
The decision has stirred a wider debate. Some scientists and industry observers see it as a technical, evidence‑based enforcement of longstanding standards for vaccine trials. Others, including company spokespeople and critics of the administration’s vaccine policies, view it as an abrupt and surprising barrier that could chill innovation in newer vaccine platforms. Internal friction at the agency has been reported—senior officials reportedly overruled some reviewers—adding to concerns about the consistency of the review process.
Practical implications
- For patients: The move delays public access to this particular candidate and could slow broader rollout of mRNA flu vaccines until regulators and manufacturers reconcile trial design expectations.
- For vaccine makers: Companies will likely revisit trial comparators, endpoints and statistical plans before submitting future applications.
- For regulators: The agency’s decision reinforces that novel technologies still need clear, well‑controlled evidence demonstrating safety and effectiveness compared with appropriate standards of care.
Moderna has requested meetings to discuss the agency’s concerns and to seek a pathway forward. It remains uncertain how long discussions will take or whether an amended filing or new trials will be required. Whatever follows will matter not just for this product, but for how regulators evaluate next‑generation vaccine platforms going forward.